Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment
Traws Pharma, Inc. (TRAW)
Company Research
Source: PR Newswire
ROCKVILLE, Md., Oct. 10, 2024 /PRNewswire/ -- Expert Systems, a leader in combining human and artificial intelligence to accelerate drug discovery, celebrates a key milestone in the development of tivoxavir marboxil, a potential best-in-class inhibitor of the highly-conserved influenza protein, CAP-dependent endonuclease (CEN), intended for use across a broad range of flu viruses. Developed by Traws Pharma, Inc. (NASDAQ: TRAW), tivoxavir marboxil (tivoxavir) showed positive topline Phase 1 safety and pharmacokinetic results, supporting its potential as a one-time treatment for influenza.Expert Systems' advanced AI-enabled drug discovery platform helped de-risk and fast-track tivoxavir's development from discovery to the clinic. Topline Phase 1 results demonstrated good overall tolerability and a pharmacokinetic profile that appears to support tivoxavir's potential use as a one-time treatment for flu, including pandemic flu. The successful outcome of this study positions tivoxavir as a
Show less
Read more
Impact Snapshot
Event Time:
TRAW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRAW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRAW alerts
High impacting Traws Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
TRAW
News
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Traws Pharma Provides Business Update and Reports Q3 2024 Financial ResultsGlobeNewswire
- Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir MarboxilGlobeNewswire
- Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro InhibitorGlobeNewswire
- Traws Pharma, Inc. Appoints Luba Greenwood to Board of DirectorsGlobeNewswire
TRAW
Earnings
- 11/14/24 - Miss
TRAW
Sec Filings
- 11/15/24 - Form S-8
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- TRAW's page on the SEC website